| Autor: |
Ön S; Department of Medical Oncology, Tepecik Training and Research Hospital, 35180 Izmir, Türkiye., Köksal B; Department of Oncology, Hacettepe University Cancer Institute, 06410 Ankara, Türkiye., Arık Z; Department of Oncology, Hacettepe University Cancer Institute, 06410 Ankara, Türkiye., Caner B; Department of Oncology, Atatürk Government Hospital, 09020 Aydın, Türkiye., Ercan Uzundal D; Department of Oncology, Gazi University Medical School Hospital, 06560 Ankara, Türkiye., Yazıcı O; Department of Oncology, Gazi University Medical School Hospital, 06560 Ankara, Türkiye., Arslan Benli B; Department of Oncology, Adana City Hospital, 1370 Adana, Türkiye., Eylemer Mocan E; Department of Oncology, Ankara University Medical School Hospital, 06620 Ankara, Türkiye., Güngör C; Department of Oncology, Selçuk University Medical School Hospital, 42130 Konya, Türkiye., Güç ZG; Department of Oncology, Katip Çelebi University Atatürk Training and Research Hospital, 35150 Izmir, Türkiye., Akay S; Department of Oncology, Izmir City Hospital, 35540 Izmir, Türkiye., Keskinkılıç M; Department of Oncology, Burdur Government Hospital, 15000 Burdur, Türkiye., Dik Avcı H; Department of Internal Medicine, Ege University Medical School Hospital, 35100 Izmir, Türkiye., Karaca Yayla B; Department of Medical Oncology, Ege University Tilay Aktaş Oncology Hospital, 35100 Izmir, Türkiye., Çakar B; Department of Medical Oncology, Ege University Tilay Aktaş Oncology Hospital, 35100 Izmir, Türkiye., Şanlı UA; Department of Medical Oncology, Ege University Tilay Aktaş Oncology Hospital, 35100 Izmir, Türkiye. |
| Abstrakt: |
(1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare and have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed to evaluate the real-life effectiveness and safety of trabectedin. (2) Methods: A retrospective multicenter study was conducted on patients who were treated with trabectedin for metastatic L-type sarcomas at ten tertiary oncology centers between 2015 and 2023. The objective response rate (ORR), disease control rate (DCR), time to treatment failure (TTF), and overall survival (OS) were evaluated in the cohort. Cox regression analysis was used to determine prognostic factors for survival. (3) Results: A total of 98 patients (52% liposarcoma and 48% leiomyosarcoma) were included in the study. The median treatment line was three (range: 1 to 6). Thirteen patients (13.3%) underwent local treatment due to oligoprogression, and dose reduction was required in seventeen patients (17.3%) due to toxicity. The ORR and DCR were 16% and 42%, respectively. The median TTF was 3 months, and the median OS was 10 months. In univariate analysis, a significantly longer median TTF was observed in patients who underwent local treatment ( p = 0.008), obtained objective responses ( p < 0.001), and underwent dose reduction ( p = 0.002). No statistical differences were observed according to the histologic subtype and metastatic site. In the multivariate analysis for OS, it was found that obtaining an objective response was a good prognostic factor ( p = 0.003), while the presence of liver metastases was associated with a poor prognosis ( p = 0.016). (4) Conclusion: Trabectedin is a suitable option for L-type sarcoma after doxorubicin-based treatments. Survival was not worse in patients who underwent dose reduction. The use of local therapies simultaneously with trabectedin can be effective. |
